Nicholas Investment Partners LP Reduces Position in Disc Medicine, Inc. $IRON

Nicholas Investment Partners LP cut its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 45.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,082 shares of the company’s stock after selling 39,921 shares during the quarter. Nicholas Investment Partners LP’s holdings in Disc Medicine were worth $3,818,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. grew its holdings in shares of Disc Medicine by 3,329.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock valued at $28,416,000 after buying an additional 347,403 shares during the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of Disc Medicine during the third quarter valued at $12,038,000. Hudson Bay Capital Management LP purchased a new stake in shares of Disc Medicine during the third quarter valued at $6,752,000. Vanguard Group Inc. grew its holdings in shares of Disc Medicine by 3.7% during the third quarter. Vanguard Group Inc. now owns 1,448,059 shares of the company’s stock valued at $95,688,000 after buying an additional 51,323 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Disc Medicine by 161.9% during the fourth quarter. SG Americas Securities LLC now owns 21,122 shares of the company’s stock valued at $1,677,000 after buying an additional 13,058 shares during the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IRON has been the topic of a number of research analyst reports. BMO Capital Markets dropped their price objective on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Tuesday, February 17th. Truist Financial reduced their price objective on Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Cantor Fitzgerald decreased their price objective on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Finally, Wedbush reissued an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $105.30.

Insider Transactions at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 5,731 shares of the company’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $66.38, for a total value of $380,423.78. Following the completion of the transaction, the insider owned 79,480 shares in the company, valued at approximately $5,275,882.40. This represents a 6.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Jean M. Franchi sold 6,257 shares of the company’s stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $69.24, for a total transaction of $433,234.68. Following the completion of the transaction, the chief financial officer owned 64,333 shares of the company’s stock, valued at approximately $4,454,416.92. This trade represents a 8.86% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 12,388 shares of company stock valued at $841,258. Insiders own 3.76% of the company’s stock.

Disc Medicine Stock Performance

Shares of IRON stock opened at $67.99 on Friday. The stock has a market cap of $2.59 billion, a PE ratio of -10.27 and a beta of 0.93. The business has a 50-day simple moving average of $68.16 and a 200-day simple moving average of $72.57. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, equities analysts expect that Disc Medicine, Inc. will post -6.74 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.